Cargando…
Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19
BACKGROUND: Cardiovascular risk factors and usage of cardiovascular medication are prevalent among coronavirus disease 2019 (COVID-19) patients. Little is known about the cardiovascular implications of COVID-19. The goal herein, was to evaluate the prognostic impact of having heart disease (HD) and...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Via Medica
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169179/ https://www.ncbi.nlm.nih.gov/pubmed/33843043 http://dx.doi.org/10.5603/CJ.a2021.0034 |
_version_ | 1783702004609056768 |
---|---|
author | Villalba, Gonzalo Cabezón Amat-Santos, Ignacio J. Dueñas, Carlos Otero, Diego López Catalá, Pablo Aparisi, Álvaro López-Pais, Javier Antonio, Carla Eugenia Cacho Candela, Jordi Muiños, Pablo Antúnez Gil, José Francisco Ferrero, Teba González Marcos, Marta Pérez-Poza, Marta Rojas, Gino García, Oscar Otero Veras, Carlos Ramos, Víctor Jiménez Uribarri, Aitor Revilla, Ana García-Granja, Pablo Elpidio Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto |
author_facet | Villalba, Gonzalo Cabezón Amat-Santos, Ignacio J. Dueñas, Carlos Otero, Diego López Catalá, Pablo Aparisi, Álvaro López-Pais, Javier Antonio, Carla Eugenia Cacho Candela, Jordi Muiños, Pablo Antúnez Gil, José Francisco Ferrero, Teba González Marcos, Marta Pérez-Poza, Marta Rojas, Gino García, Oscar Otero Veras, Carlos Ramos, Víctor Jiménez Uribarri, Aitor Revilla, Ana García-Granja, Pablo Elpidio Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto |
author_sort | Villalba, Gonzalo Cabezón |
collection | PubMed |
description | BACKGROUND: Cardiovascular risk factors and usage of cardiovascular medication are prevalent among coronavirus disease 2019 (COVID-19) patients. Little is known about the cardiovascular implications of COVID-19. The goal herein, was to evaluate the prognostic impact of having heart disease (HD) and taking cardiovascular medications in a population diagnosed of COVID-19 who required hospitalization. Also, we studied the development of cardiovascular events during hospitalization. METHODS: Consecutive patients with definitive diagnosis of COVID-19 made by a positive real time-polymerase chain reaction of nasopharyngeal swabs who were admitted to the hospital from March 15 to April 14 were included in a retrospective registry. The association of HD with mortality and with mortality or respiratory failure were the primary and secondary objectives, respectively. RESULTS: A total of 859 patients were included in the present analysis. Cardiovascular risk factors were related to death, particularly diabetes mellitus (hazard ratio in the multivariate analysis: 1.810 [1.159–2.827], p = 0.009). A total of 113 (13.1%) patients had HD. The presence of HD identified a group of patients with higher mortality (35.4% vs. 18.2%, p < 0.001) but HD was not independently related to prognosis; renin–angiotensin–aldosterone system inhibitors, calcium channel blockers, diuretics and beta-blockers did not worsen prognosis. Statins were independently associated with decreased mortality (0.551 [0.329–0.921], p = 0.023). Cardiovascular events during hospitalization identified a group of patients with poor outcome (mortality 31.8% vs. 19.3% without cardiovascular events, p = 0.007). CONCLUSIONS: The presence of HD is related to higher mortality. Cardiovascular medications taken before admission are not harmful, statins being protective. The development of cardiovascular events during the course of the disease is related to poor outcome. |
format | Online Article Text |
id | pubmed-8169179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Via Medica |
record_format | MEDLINE/PubMed |
spelling | pubmed-81691792021-06-02 Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19 Villalba, Gonzalo Cabezón Amat-Santos, Ignacio J. Dueñas, Carlos Otero, Diego López Catalá, Pablo Aparisi, Álvaro López-Pais, Javier Antonio, Carla Eugenia Cacho Candela, Jordi Muiños, Pablo Antúnez Gil, José Francisco Ferrero, Teba González Marcos, Marta Pérez-Poza, Marta Rojas, Gino García, Oscar Otero Veras, Carlos Ramos, Víctor Jiménez Uribarri, Aitor Revilla, Ana García-Granja, Pablo Elpidio Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto Cardiol J COVID-19 BACKGROUND: Cardiovascular risk factors and usage of cardiovascular medication are prevalent among coronavirus disease 2019 (COVID-19) patients. Little is known about the cardiovascular implications of COVID-19. The goal herein, was to evaluate the prognostic impact of having heart disease (HD) and taking cardiovascular medications in a population diagnosed of COVID-19 who required hospitalization. Also, we studied the development of cardiovascular events during hospitalization. METHODS: Consecutive patients with definitive diagnosis of COVID-19 made by a positive real time-polymerase chain reaction of nasopharyngeal swabs who were admitted to the hospital from March 15 to April 14 were included in a retrospective registry. The association of HD with mortality and with mortality or respiratory failure were the primary and secondary objectives, respectively. RESULTS: A total of 859 patients were included in the present analysis. Cardiovascular risk factors were related to death, particularly diabetes mellitus (hazard ratio in the multivariate analysis: 1.810 [1.159–2.827], p = 0.009). A total of 113 (13.1%) patients had HD. The presence of HD identified a group of patients with higher mortality (35.4% vs. 18.2%, p < 0.001) but HD was not independently related to prognosis; renin–angiotensin–aldosterone system inhibitors, calcium channel blockers, diuretics and beta-blockers did not worsen prognosis. Statins were independently associated with decreased mortality (0.551 [0.329–0.921], p = 0.023). Cardiovascular events during hospitalization identified a group of patients with poor outcome (mortality 31.8% vs. 19.3% without cardiovascular events, p = 0.007). CONCLUSIONS: The presence of HD is related to higher mortality. Cardiovascular medications taken before admission are not harmful, statins being protective. The development of cardiovascular events during the course of the disease is related to poor outcome. Via Medica 2021-05-25 /pmc/articles/PMC8169179/ /pubmed/33843043 http://dx.doi.org/10.5603/CJ.a2021.0034 Text en Copyright © 2021 Via Medica https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. |
spellingShingle | COVID-19 Villalba, Gonzalo Cabezón Amat-Santos, Ignacio J. Dueñas, Carlos Otero, Diego López Catalá, Pablo Aparisi, Álvaro López-Pais, Javier Antonio, Carla Eugenia Cacho Candela, Jordi Muiños, Pablo Antúnez Gil, José Francisco Ferrero, Teba González Marcos, Marta Pérez-Poza, Marta Rojas, Gino García, Oscar Otero Veras, Carlos Ramos, Víctor Jiménez Uribarri, Aitor Revilla, Ana García-Granja, Pablo Elpidio Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19 |
title | Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19 |
title_full | Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19 |
title_fullStr | Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19 |
title_full_unstemmed | Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19 |
title_short | Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19 |
title_sort | impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in covid-19 |
topic | COVID-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169179/ https://www.ncbi.nlm.nih.gov/pubmed/33843043 http://dx.doi.org/10.5603/CJ.a2021.0034 |
work_keys_str_mv | AT villalbagonzalocabezon impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT amatsantosignacioj impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT duenascarlos impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT oterodiegolopez impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT catalapablo impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT aparisialvaro impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT lopezpaisjavier impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT antoniocarlaeugeniacacho impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT candelajordi impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT muinospabloantunez impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT giljosefrancisco impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT ferrerotebagonzalez impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT marcosmarta impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT perezpozamarta impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT rojasgino impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT garciaoscarotero impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT verascarlos impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT ramosvictorjimenez impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT uribarriaitor impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT revillaana impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT garciagranjapabloelpidio impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT gomezitziar impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT gonzalezjuanateyjoseramon impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 AT sanromanjalberto impactofthepresenceofheartdiseasecardiovascularmedicationsandcardiaceventsonoutcomeincovid19 |